Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options, PDMR dealing and Total Voting Rights

Gaithersburg, Maryland, November 17, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that Doug Doerfler, Chief Executive Officer and Founder of the Company and Amanda Murphy, Chief Financial Officer, have exercised options over 350,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 350,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock"), together with 100,000 shares previously owned by Doug Doerfler, have been sold by Doug Doerfler and Amanda Murphy at a price range between of $12.08 and $12.66 per Common Stock ("Sale"). The sold shares represent approximately 10% and 12% of Doug Doerfler's and Amanda Murphy total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company and Amanda Murphy holds 0 shares of Common Stock.  Following the Exercise, Doug Doerfler and Amanda Murphy hold a further 2,516,680 and 1,065,470 options over Common Stock respectively.

Total voting rights

The 350,000 New Common Stock have been admitted to trading on AIM pursuant to the Block Listing announced by the Company on September 6, 2021. The New Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 101,168,137 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 100,838,137 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 330,000.

MaxCyte Contacts:

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them: